In 2012, Watanabe et al. tested the effects of DNA thioaptamers targeting high mobility group A (HMGA) proteins HMGA1 and HMGA2 in pancreatic cancer cell lines [143]. The gene discussed is HMGA1; the disease is pancreatic neoplasm.